Daiichi Sankyo Company, Limited, a global pharmaceutical company, announced that the antiplatelet agent Efient 3.75mg/5mg tablets (prasugrel hydrochloride), which was launched in Japan in May 2014, has had its prescription period limitation of 14 days lifted based on a notification received from the Japanese Ministry of Health, Labour and Welfare.

Efient is an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Limited. The results of clinical trials in Japanese patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI) demonstrated that Efient reduces the incidence of ischemic events from the perioperative period of PCI by rapidly reducing platelet aggregation activity.

Through the lifting of the prescription period limitation of Efient, Daiichi Sankyo aims to benefit even more patients and healthcare professionals involved with ischemic heart disease therapy.

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. The company provide innovative products and services in more than 20 countries around the world.